Outset Medical, Inc. (NASDAQ:OM) Director D Keith Grossman Sells 38,117 Shares

Outset Medical, Inc. (NASDAQ:OM) Director D Keith Grossman sold 38,117 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $3.78, for a total value of $144,082.26. Following the completion of the sale, the director now owns 47,805 shares in the company, valued at $180,702.90. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Outset Medical Trading Up 2.4 %

Shares of OM stock traded up $0.09 during trading hours on Monday, reaching $3.82. The company had a trading volume of 739,365 shares, compared to its average volume of 1,175,002. The company has a 50 day moving average of $2.86 and a 200 day moving average of $3.73. The company has a debt-to-equity ratio of 2.11, a current ratio of 6.42 and a quick ratio of 5.32. The firm has a market cap of $197.58 million, a price-to-earnings ratio of -1.13 and a beta of 1.85. Outset Medical, Inc. has a 1-year low of $1.92 and a 1-year high of $24.13.

Outset Medical (NASDAQ:OM) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.13). Outset Medical had a negative net margin of 134.93% and a negative return on equity of 120.67%. The firm had revenue of $28.17 million during the quarter, compared to the consensus estimate of $30.55 million. On average, equities research analysts anticipate that Outset Medical, Inc. will post -2.23 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. BTIG Research began coverage on Outset Medical in a research note on Monday, April 8th. They issued a “buy” rating and a $6.00 price objective on the stock. CL King upgraded Outset Medical from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a research report on Friday, April 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $5.42.

Institutional Trading of Outset Medical

A number of large investors have recently made changes to their positions in the company. State Board of Administration of Florida Retirement System grew its holdings in shares of Outset Medical by 33.4% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 18,842 shares of the company’s stock valued at $42,000 after acquiring an additional 4,720 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Outset Medical by 1,317.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 8,790 shares of the company’s stock valued at $48,000 after acquiring an additional 8,170 shares in the last quarter. RPO LLC bought a new position in shares of Outset Medical in the 4th quarter valued at about $76,000. Valeo Financial Advisors LLC bought a new position in shares of Outset Medical in the 4th quarter valued at about $117,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Outset Medical in the 4th quarter valued at about $161,000.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.